Scholarlink

Purpose of Review <p>REM sleep behavior disorder (RBD) is a well-established prodromal marker of α-synucleinopathies, including Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy. Over 80% of individuals with isolated RBD (iRBD) eventually phenoconvert to a neurodegenerative disease, making it a valuable target for early diagnosis and intervention. This review highlights advances in the epidemiology, pathophysiology, and clinical features of RBD, and synthesizes evidence from longitudinal studies linking iRBD to phenoconversion risk.</p> Recent Findings <p>Emerging biomarkers—including neurophysiologic, neuroimaging, fluid, tissue, autonomic, cognitive, and genetic markers —enhance risk stratification, track disease progression and provide insight into disease mechanisms. Neuroanatomical and molecular insights support RBD as an early manifestation of synuclein pathology.</p> Summary <p>With growing global research networks and a long prodromal window, iRBD represents an ideal population for neuroprotective trials. Standardization of diagnostic criteria and integration of multimodal biomarkers will be essential to advancing early detection and disease-modifying strategies in α-synucleinopathies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Advances in the Understanding of REM Sleep Behavior Disorder as a Biomarker for Neurodegenerative Diseases

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月25日

查看全文
  • Sikawat Thanaviratananich,
  • Andrea Nguyen,
  • Matthew Chaung,
  • Jeffrey S Patterson,
  • Joyce K Lee-Iannotti

摘要

Purpose of Review

REM sleep behavior disorder (RBD) is a well-established prodromal marker of α-synucleinopathies, including Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy. Over 80% of individuals with isolated RBD (iRBD) eventually phenoconvert to a neurodegenerative disease, making it a valuable target for early diagnosis and intervention. This review highlights advances in the epidemiology, pathophysiology, and clinical features of RBD, and synthesizes evidence from longitudinal studies linking iRBD to phenoconversion risk.

Recent Findings

Emerging biomarkers—including neurophysiologic, neuroimaging, fluid, tissue, autonomic, cognitive, and genetic markers —enhance risk stratification, track disease progression and provide insight into disease mechanisms. Neuroanatomical and molecular insights support RBD as an early manifestation of synuclein pathology.

Summary

With growing global research networks and a long prodromal window, iRBD represents an ideal population for neuroprotective trials. Standardization of diagnostic criteria and integration of multimodal biomarkers will be essential to advancing early detection and disease-modifying strategies in α-synucleinopathies.